The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of perioperative capecitabine plus oxaliplatin for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601).
 
Atsushi Yasuda
No Relationships to Disclose
 
Jin Matsuyama
No Relationships to Disclose
 
Tetsuji Terazawa
No Relationships to Disclose
 
Masahiro Goto
Honoraria - Daiichi Sankyo; Eisai; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma; Lilly; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Ryohei Kawabata
No Relationships to Disclose
 
Shunji Endo
No Relationships to Disclose
 
Motohiro Imano
No Relationships to Disclose
 
Shoichiro Fujita
No Relationships to Disclose
 
Yusuke Akamaru
No Relationships to Disclose
 
Hirokazu Taniguchi
No Relationships to Disclose
 
Mitsutoshi Tatsumi
No Relationships to Disclose
 
Sang-Woong Lee
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Yukinori Kurokawa
Honoraria - Daiichi Sankyo; Johnson & Johnson; Medtronic; MSD; Olympus; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Yakult Honsha
 
Toshio Shimokawa
No Relationships to Disclose
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Kazumasa Fujitani
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)